

Disease Site & Study #	Sunday, October 24, 2021	Time/Location
H&N NRG-HN001	<p><b>Title:</b> <i>Knowledge-based models for NRG HN001 proton plan quality analysis</i></p> <p><b>Presenter:</b> Huaizhi Geng</p> <p><b>Presentation:</b> 2271</p>	<p><b>Location:</b> McCormick Place West, Outside Room W375</p> <p><b>Session:</b> Session 02 - Radiation and Cancer Physics - Plan Optimization and Digital Health Innovation</p> <p><b>Date/Time:</b> Oct 24, 4:45 PM</p> <p><b>Duration:</b> 1 hour 15 minutes</p> <p><b>Poster Viewing Q &amp; A</b></p>
GU-Prostate NRG/ROG 0815	<p><b>Title:</b> <i>Dose escalated radiotherapy (RT) alone or in combination with short-term total androgen suppression (TAS) for intermediate risk prostate cancer: patient reported outcomes (PROs) from the NRG Oncology/ROG 0815 randomized trial</i></p> <p><b>Presenter:</b> Benjamin Movsas</p> <p><b>Presentation:</b> 4</p>	<p><b>Location:</b> McCormick Place West, Room W375 a/b/c/d</p> <p><b>Session:</b> Clinical Trials Session</p> <p><b>Date/Time:</b> Oct 24, 3:15 PM</p> <p><b>Duration:</b> 10 minutes</p> <p><b>Oral</b></p>
Disease Site & Study #	Monday, October 25, 2021	Time/Location
GU-Prostate NRG-GU003	<p><b>Title:</b> <i>Primary endpoint analysis of a randomized phase III trial of hypofractionated versus conventional post-prostatectomy radiotherapy: NRG Oncology GU003</i></p> <p><b>Presenter:</b> Mark Buyyounouski</p> <p><b>Presentation:</b> 3</p>	<p><b>Location:</b> McCormick Place West, Room W375 a/b/c/d</p> <p><b>Session:</b> Plenary Session</p> <p><b>Date/Time:</b> Oct 25, 4:25 PM</p> <p><b>Duration:</b> 10 minutes</p> <p><b>Plenary Oral</b></p>
GI-Rectal NRG/GI002	<p><b>Title:</b> <i>A prospective validation of the magnetic resonance tumor regression grade (MR-TRG) and correlation with pathologic endpoints score in NRG Oncology GI002</i></p> <p><b>Presenter:</b> William Hall</p> <p><b>Presentation:</b> 71</p>	<p><b>Location:</b> McCormick Place West, Room W375e</p> <p><b>Session:</b> GI 1 - Trust but Verify: Quality Assurance and Quality of Life in GI Cancers</p> <p><b>Date/Time:</b> Oct 25, 2:00 PM</p> <p><b>Duration:</b> 10 minutes</p> <p><b>Oral</b></p>
GU-Prostate NRG/ROG 9406 NRG/ROG 0126	<p><b>Title:</b> <i>Body composition and risk of all-cause mortality in men treated with radiation therapy for prostate cancer: a pooled analysis of NRG/ROG 9406 and NRG/ROG 0126</i></p> <p><b>Presenter:</b> Andrew Macdonald</p> <p><b>Presentation:</b> 2576</p>	<p><b>Location:</b> McCormick Place West, Outside Room W375</p> <p><b>Session:</b> Session 05 - Genitourinary Cancer, Hematologic Malignancies, and Sarcoma and Cutaneous Tumors</p> <p><b>Date/Time:</b> Oct 25, 1:30 PM</p> <p><b>Duration:</b> 1 hour 15 minutes</p> <p><b>Poster</b></p>
GU-Prostate NRG/ROG 0815	<p><b>Title:</b> <i>Dose escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG Oncology/ROG 0815 randomized trial</i></p> <p><b>Presenter:</b> Daniel Krauss</p> <p><b>Presentation:</b> 1</p>	<p><b>Location:</b> McCormick Place West, Room W375 a/b/c/d</p> <p><b>Session:</b> Plenary Session</p> <p><b>Date/Time:</b> Oct 25, 3:45 PM</p> <p><b>Duration:</b> 10 minutes</p> <p><b>Plenary Oral</b></p>
GI-Pancreas NRG/ROG 0848	<p><b>Title:</b> <i>Analysis of radiation therapy quality assurance in NRG Oncology RTOG 0848</i></p> <p><b>Presenter:</b> Leila Tchelebi</p> <p><b>Presentation:</b> 76</p>	<p><b>Location:</b> McCormick Place West, Room W375e</p> <p><b>Session:</b> GI 1 - Trust but Verify: Quality Assurance and Quality of Life in GI Cancers</p> <p><b>Date/Time:</b> Oct 25, 2:50 PM</p> <p><b>Duration:</b> 10 minutes</p> <p><b>Oral</b></p>

Disease Site & Study #	Tuesday, October 26, 2021	Time/Location
GU-Bladder  NRG/ROG 0926	<b>Title:</b> <i>NRG Oncology/RTOG 0926: phase II protocol for patients with stage T1 bladder cancer to evaluate selective bladder preserving treatment by radiation therapy concurrent with radiosensitizing chemotherapy following a thorough transurethral surgical re-staging</i> <b>Presenter:</b> Douglas Dahl <b>Presentation:</b> 1078	<b>Location:</b> McCormick Place West, Room W178 a/b <b>Session:</b> GU3 -GU Smorgasbord <b>Date/Time:</b> Oct 26, 1:15 PM <b>Duration:</b> 5 minutes <b>Quick Pitch Oral</b>
Lung  NRG-LU005	<b>Title:</b> <i>NRG Oncology/Alliance LU005: A phase II/III randomized study of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer</i> <b>Presenter:</b> Kristin Higgins <b>Presentation:</b> 2975	<b>Location:</b> McCormick Place West, Outside Room W375 <b>Session:</b> Session 08 - Lung Cancer/Thoracic Malignancies and Palliative Care <b>Date/Time:</b> Oct 26, 3:30 PM <b>Duration:</b> 1 hour 15 minutes <b>Poster</b>
GU-Prostate  NRG/ROG 9202 NRG/ROG 9413 NRG/ROG 9902	<b>Title:</b> <i>Validation of a 22-gene genomic classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 phase III randomized trials: a biopsy-based individual patient meta-analysis in high-risk prostate cancer</i> <b>Presenter:</b> Paul Nguyen <b>Presentation:</b> 95	<b>Location:</b> McCormick Place West, Room W181 a/b/c <b>Session:</b> GU 1 - Biomarkers and Salvage RT <b>Date/Time:</b> Oct 26, 8:35 AM <b>Duration:</b> 10 minutes <b>Oral</b>
Lung  NRG-LU006	<b>Title:</b> <i>A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG LU-006)</i> <b>Presenter:</b> Andreas Rimner <b>Presentation:</b> 2961	<b>Location:</b> McCormick Place West, Outside Room W375 <b>Session:</b> Session 08 - Lung Cancer/Thoracic Malignancies and Palliative Care <b>Date/Time:</b> Oct 26, 3:30 PM <b>Duration:</b> 1 hour 15 minutes <b>Poster Viewing Q &amp; A</b>
Disease Site & Study #	Wednesday, October 27, 2021	Time/Location
H&N  NRG/ROG 0022	<b>Title:</b> <i>Final report of NRG Oncology RTOG 0022: A phase I/II study of conformal and intensity modulated radiation for oropharyngeal cancer</i> <b>Presenter:</b> Adam Garden <b>Presentation:</b> 1098	<b>Location:</b> McCormick Place West, Room W178 a/b <b>Session:</b> H&N 2 - Head and Neck Cancer in 2021: updates and new directions <b>Date/Time:</b> Oct 27, 1:10 PM <b>Duration:</b> 5 minutes <b>Quick Pitch Oral</b>
H&N  NRG-HN005	<b>Title:</b> <i>Deep learning auto-segmentation model for HN005 contour quality assurance</i> <b>Presenter:</b> Huaizhi Geng <b>Presentation:</b> 3055	<b>Location:</b> McCormick Place West, Outside Room W375 <b>Session:</b> Session 09 - Physics - Treatment Techniques and Patient Safety <b>Date/Time:</b> Oct 27, 10:30 AM <b>Duration:</b> 1 hour 15 minutes <b>Poster Viewing Q &amp; A</b>
GI-Pancreas  NRG/ROG 9704	<b>Title:</b> <i>High SMAD4 expression is associated with better clinical outcomes in patients with resectable pancreatic cancer: an analysis of NRG Oncology/RTOG 9704</i> <b>Presenter:</b> Terence Williams <b>Presentation:</b> 1103	<b>Location:</b> McCormick Place West, Room W178 a/b <b>Session:</b> GI 3 - Where Are We Going with Pancreatic Cancer Radiotherapy? Novel Biomarkers and Dosing Strategies <b>Date/Time:</b> Oct 27, 10:35 AM <b>Duration:</b> 5 minutes <b>Quick Pitch Oral</b>

GI-Pancreas  NRG/RTOG 9704	<b>Title:</b> <i><math>\beta</math>-catenin is independently associated with outcome in pancreatic cancer: An analysis of NRG Oncology/RTOG 9704</i> <b>Presenter:</b> Chandan Guha <b>Presentation:</b> 1104	<b>Location:</b> McCormick Place West, Room W178 a/b <b>Session:</b> GI 3 - Where Are We Going with Pancreatic Cancer Radiotherapy? Novel Biomarkers and Dosing Strategies <b>Date/Time:</b> Oct 27, 10:40 AM <b>Duration:</b> 5 minutes <b>Quick Pitch Oral</b>
----------------------------------	---	--